HAMP and hemochromatosis type 1: Our experimental results suggested that the BMP4 p.H251Y and p.R269Q variants decreased hepcidin levels via the downregulation of the BMP/SMAD signaling pathway, indicating that the BMP4 p.H251Y and p.R269Q variants may be novel pathogenic factors of hemochromatosis.